(PRESS RELEASE) JACKSONVILLE, FL — Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson MedTech Companies, was recognized as the winner of Fast Company’s 2022 World Changing Ideas Awards in the Wellness category for ACUVUE Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen). Each lens contains 19 mcg ketotifen. Fast Company also selected ACUVUE Theravision with Ketotifen for an honorable mention in both the Health and Enduring Impact: 15+ Years in Business categories.
ACUVUE Theravision with Ketotifen are daily disposable contact lenses indicated for the prevention of ocular itch due to allergic conjunctivitis and provide vision correction in patients who do not have red eyes, who are suitable for contact lens wear and who do not have more than 1.00 D of astigmatism.
The World Changing Ideas Awards honor products, concepts, companies, policies, and designs that are pursuing innovation for the good of society and the planet. ACUVUE Theravision with Ketotifen was recognized as a winner from a pool of more than 2,997 entries across health, wellness, technology, transportation, education, and more. Fast Company’s Summer 2022 issue (on newsstands May 10) will highlight some of the world’s most inventive companies tackling the most pressing global challenges.
“At Johnson & Johnson Vision, we are guided by an incredible sense of purpose and a bold ambition to redefine healthy sight for life,” said Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision. “Congratulations to all our teams, patients, and eye care professionals who have been instrumental in introducing this entirely new category of contact lens. We are constantly pushing the boundaries of what’s possible to improve eye health, and the recognition of ACUVUE Theravision with Ketotifen as a World Changing Idea is both an honor and a summons for us to continue anticipating and creating solutions to help more people see better, connect better, live better.”
Within the U.S., approximately 40 percent of contact lens wearers suffer from itchy eyes due to ocular allergies,§ and nearly 8 out of 10 contact lenses wearers with eye allergies agree that they are frustrated when allergies interfere with their normal contact lens wear.** While allergy eye drops are a very common treatment, 1 in 2 contact lens wearers say that the drops are inconvenient to use.††
“Johnson & Johnson Vision scientists worked tirelessly to perfect the formula of infusing medication into a contact lens without compromising its effectiveness in relieving ocular allergic itch and providing vision correction,” said Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision. “ACUVUE Theravision with Ketotifen brings an innovative solution for people who suffer from itchy eyes due to allergies and may help to end the disruption from not being able to wear contacts due to allergic eye itch.”
ACUVUE Theravision with Ketotifen provides relief of itchy allergy eyes and vision correction in one step. The Phase 3 studies of ACUVUE Theravision with Ketotifen showed a clinically and statistically meaningful reduction in itchy allergy eyes compared to non-medicated lenses, as quickly as 3 minutes after lens insertion and lasting up to 12 hours. However, the lens may be worn for longer than 12 hours for vision correction.
ACUVUE Theravision with Ketotifen was approved by the U.S. Food and Drug Administration in February 2022, and the lenses are available to patients in Japan and Canada, following regulatory approvals in 2021.
For more information and to stay informed of product availability, visit: here. For full Prescribing Information, click here and to view the Patient Instruction Guide click here.